

**Table EU Approved biosimilars by molecule November 2019**  
(not available in all EU-countries) (status November 4, 2019; 55 products)

Molecule	Reference	Biosimilar(s)
Adalimumab	Humira	Amgevita, Halimatoz, Hefiya, Hulio, Hyrimoz, Idacio, Imraldi, Kromea
bevacizumab	Avastin	MVasi, Zirabev
Enoxaparine	Clexane	Inhixa, Thorinane
Epoetine alfa	Epex	Absaemed, Binocrit, Epoetin alfa Hexal, Retacrit, Silapo
Etanercept	Enbrel	Benepali, Erelzi
Filgrastim	Neupogen	Accofil, Filgrastim Hexal, Grastofil, Nivestim, Ratiograstim, Tevagrastim, Zarzio
Follitropin alfa	Gonal-f	Bemfola, Ovaleap
Infliximab	Remicade	Flixabi, Inflectra, Remsima, Zessly
Insulin glargine	Lantus	Abasaglar, Semglee
Insulin Lispro	Humalog	Insulin Lispro Sanofi
Pegfilgrastim	Neulasta	Fulphila, Grasustek, Pegfilgrastim Mundipharma, Pelgraz, Pelmeg, Udenyca, Ziextenzo
Rituximab	Mabthera IV	Blitzima, Ritemvia, Rixathon, Riximyo, Truxima
Somatropine	Genotropin	Omnitrope
Teriparatide	Forsteo	Movymia, Terrosa
Trastuzumab	Herceptin IV	Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera

Source: EMA website

[https://www.ema.europa.eu/medicines/field\\_ema\\_web\\_categories%253Aname\\_field/Human/ema\\_group\\_types/ema\\_medicine/field\\_ema\\_med\\_status/authorised36/ema\\_medicine\\_types/field\\_ema\\_med\\_biosimilar/search\\_api\\_aggregation\\_ema\\_medicine\\_types/field\\_ema\\_med\\_biosimilar](https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar)

Accessed: 11 November 2019

For a comparison with US/FDA (May 2019) see:

<https://www.biosimilarsip.com/2019/05/07/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-4/>

15 Biosimilar-molecules in the licensing pipeline at EMA (Status: 4/11/2019)

Adalimumab (1x), bevacizumab (2), etanercept (1x), insulin aspart (2), pegfilgrastim (1), rituximab (3x), teriparatide (3), trastuzumab (2).